All In Biotech

Drug Trial Radar · NCT07311148

A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 40 Years and Older

A Phase Ⅱ, Randomized, Observer-blinded, Parallel-Controlled Clinical Trial to Assess the Immunogenicity and Safety of the Recombinant Zoster Vaccine, LYB004 in Adults Aged 40 Years and Older

Last checked: Nov 19, 2026Latest source record: Dec 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 840 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

840

Planned (sponsor's estimate)

Start

Oct 23, 2025

Primary completion

Jan 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Dec 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase 2 study in China will evaluate the immunogenicity and safety of the Recombinant Zoster Vaccine, LYB004 in adults aged 40 years and older.

Conditions

  • Herpes Zoster (HZ)
  • Shingles
  • VZV
  • Recombinant Zoster Vaccine

Interventions

  • Low dose antigen and low dose adjuvant of LYB004Biological

    0.5 mL per dose, containing 25 μg VZV-gEM adjuvanted with A01C.

  • Low dose antigen and high dose adjuvant of LYB004Biological

    0.5 mL per dose, containing 25 μg VZV-gEM adjuvanted with A01B.

  • High dose antigen and low dose adjuvant of LYB004Biological

    0.5 mL per dose, containing 50 μg VZV-gEM adjuvanted with A01C.

  • High dose antigen and high dose adjuvant of LYB004Biological

    0.5 mL per dose, containing 50 μg VZV-gEM adjuvanted with A01B.

  • PlaceboBiological

    0.5 mL per dose, without antigen and adjuvant.

  • Positive controlBiological

    0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The geometric mean concentration (GMC) of anti-glycoprotein E (gE) antibodyTime frame: 30 days after second vaccination
  2. The geometric mean titer (GMT) of anti-VZV antibodyTime frame: 30 days after second vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hengnan County Center for Disease Control and Prevention

    Hengyang, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.